Loading clinical trials...

ACTIVE_NOT_RECRUITING

Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life

Breast Cancer and the Workforce: Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life (BCW)

NCT01134172•Memorial Sloan Kettering Cancer Center

View on ClinicalTrials.gov

Summary

The purpose of this study is to learn more about how being treated for breast cancer affects patients' employment, financial situation, and quality of life on a short-term basis and on a long term basis. Most studies of employment after breast cancer have focused on Caucasian women.This study will evaluate the impact of breast cancer on the lives of women from different ethnic groups.

Eligibility

Age

18 - 64 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•Breast cancer survivors
•Pathologic diagnosis of stage I-III breast cancer
•Paid employment (full time or part time) at time of consent or in the three months prior to diagnosis
•Age 18 to 64 years (inclusive)
•The ability to give informed consent in Chinese (Mandarin), English, Korean, or Spanish.at MSK, New York Presbyterian Queens and Queens Medical Associates At NYC Health \& Hospitals/ Lincoln Medical Center, patients must be able to give consent in English or Spanish.
•At the time of enrollment, participants must still be undergoing chemotherapy, undergoing radiation therapy, or planning surgery unless surgery is to be the only treatment modality. Those for whom treatment consists of surgery alone may have had their operation no more than 2 months prior to study enrollment. Participants need not have undergone surgical reconstruction prior to enrollment if the plan is to delay this procedure until after primary treatment is completed.
•Comparison group
•Paid employment (full time or part time) at the time of consent
•Age 18 to 64 years (inclusive) and within an age range that is 5 years above or below that of the nominating or matched survivor
•The ability to give informed consent in the same language as the nominating survivor
+2 more criteria

Exclusion Criteria

•N/A

Locations (12)

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, United States

Woodhull Medical and Mental Health Center

Brooklyn, New York, United States

Memorial Sloan Kettering Commack

Commack, New York, United States

Queens Medical Associates

Fresh Meadows, New York, United States

Memorial Sloan Kettering Westchester

Harrison, New York, United States

Memorial Sloan Kettering at Ralph Lauren

New York, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Bellevue Hospital Center

New York, New York, United States

New York Presbyterian Queens

Queens, New York, United States

Key Dates

Start Date

May 1, 2010

Primary Completion Date

May 1, 2026

Completion Date

May 1, 2026

Last Updated

June 26, 2025

Enrollment

935

ACTUAL participants

Conditions

Breast Cancer

Interventions

survey web-based or telephone interview

BEHAVIORAL

survey web-based or telephone interview

BEHAVIORAL

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

View study

RECRUITINGPHASE1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 26, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer